Updates at Antiverse

Updates at Antiverse

Home
Archive
About
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
The Multi-Target Partnership And Licensing Agreement Combines the Companies' GPCR Expertise To Bring Transformative Therapies To Patients.
 • AntiverseHQ
Data Constraints in Drug Discovery
Antiverse Newsletter October 2024
 • AntiverseHQ
Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform
This Brings The Company's Total Financing To £7.2M ($10.1M). The Funding Will Progress Antibodies Targeting Several G-Protein Coupled Receptors and Ion…
 • AntiverseHQ
What You Should Know About Weight Loss Drugs (If You Work In Pharma or Biotech)
Antiverse Newsletter August 2024
 • AntiverseHQ
How to Discover Biologics for Challenging Targets
Antiverse Newsletter July 2024
 • AntiverseHQ
Why are pharmaceutical companies turning to artificial intelligence for drug discovery?
Our top 5 reasons, based on our own research and previous collaborations with pharmaceutical companies.
 • AntiverseHQ
Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics
Two antibodies showing high specificity for PD-1 are now progressing to preclinical development as checkpoint inhibitors in oncology.
 • AntiverseHQ
Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform
Seven human G-protein coupled receptor antibodies were characterised, showing high affinity and blocking function. $3 million USD investments will…
 • AntiverseHQ
Updates at Antiverse
Updates at Antiverse
Engineering the future of drug discovery. Antiverse's media platform for all the latest updates.

Updates at Antiverse

AboutArchive
© 2026 AntiverseHQ · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture